Cite
HARVARD Citation
Qin, S. et al. (n.d.). 776TiPGlobal phase III study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress. Annals of oncology. p. . [Online].